The Role of Statin Therapy in the Primary Prevention of Cardiovascular Events: A Review of Pivotal Trial Evidence

Abstract

Introduction: Atherosclerotic cardiovascular disease is a leading cause of global mortality. While the efficacy of statin therapy for secondary prevention in patients with established disease was well-accepted, its role in primary prevention for individuals without prior cardiovascular events was a critical area of clinical investigation.

Literature Review: A review of pivotal randomized trials reveals the progressive confirmation of statin efficacy in primary prevention. Landmark studies demonstrated a significant reduction in major cardiovascular events in key high-risk populations, including individuals with hypertension and those with type 2 diabetes. Large-scale meta-analyses further substantiated the benefit of LDL cholesterol lowering across a broad spectrum of baseline risk. The paradigm was further expanded by a groundbreaking trial which showed that statin therapy was highly effective in individuals with low or normal cholesterol levels but with evidence of systemic inflammation, as indicated by elevated high-sensitivity C-reactive protein. This established that cardiovascular benefit extended beyond lipid levels alone.

Conclusion: This body of evidence firmly established statin therapy as a cornerstone of primary cardiovascular prevention. The findings broadened the indications for treatment to a wide range of at-risk individuals, confirming the benefit of lowering LDL cholesterol and introducing the concept of treating inflammation to prevent first-time cardiovascular events.